GlaxoSmithKline chooses not to exercise right to MET/RET/VEGFR2 inhibitor XL184

GlaxoSmithKline has decided not to exercise its option to license MET/RET/VEGFR2 inhibitor from Exelixis

GSK respond to negative NICE recommendation on Tykerb

GSK have responded to the NICE recommendationi that Tyverb (lapatinib) should not be used in the NHS, except in clinical trials. The company says “we strongly believe that the wrong decision has been made for patients, doctors and the NHS”

GSK publish series of Rho kinase I (ROCK1) inhibitors

GSK have published a series of dihydropyrimidine Rho kinase I (ROCK1) inhibitors

GSK publish series of PLK-1 inhibitors

GSK have published a seies of Imidazo[5,1-f][1,2,4]triazin-2-amine polo-like kinase 1inhibitors

GSK publish seres of CDK inhibitors

GSK have published a series of pyrazolo[1,5-b]pyridazine CDK inhibitors

Pazopanib demonstrates efficacy in Sarcoma and Ovarian cancer

Phase III data presented at the European of Medical Oncology (ESMO) show pazopanib to be effective in soft tissue sarcoma (STS), epithelial ovarian cancer, and non small cell lung cancer. GSK plan to initiate Phase III trials in other cancer types.

GSKs Tykerb (lapatinib) effective in advanced head and neck cancer

Phase II data presented at the European of Medical Oncology (ESMO) show that GSK’s Tykerb (lapatinib) is effective in advanced head and neck cancer

Combination of a sheddase inhibitor INCB3619 with lapatinib improves anti-tumor effect

Researchers have shown that the addition of sheddase inhibitor INCB3619 to lapatinib treated cells increases antitumor activity

GSK disclose discovery of Pazopanib

GSK have published the sysnthesis of VEGF inhibitor Pazopanib under clinical development for renal-cell cancer and other solid tumors.

Exelixis and GlaxoSmithKline Conclude Six-Year Discovery and Development Collaboration

Exelixis and GlaxoSmithKline will conclude their six-year collaboration in October 2008. GSK will have the right to choose one of the following compounds for for further development and commercialization: XL184, XL281, XL228, XL820, and XL844. GSK previously selected XL880 from the collaboration